Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • NewAmsterdam Pharma

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

    Approximately 38.4 million people in the US are affected by diabetes

    - PMLiVE

    Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

    The companies will aim to discover and develop new therapeutics for the group of disorders

    - PMLiVE

    Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition

    The deal will give Lilly access to Verve’s pipeline of gene editing medicines for atherosclerotic CVD

    - PMLiVE

    NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study

    The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate

    - PMLiVE

    Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease

    Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year

    - PMLiVE

    Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

    Cardiovascular diseases result in an estimated 17.9 million global deaths each year

    - PMLiVE

    AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn

    Dyslipidaemia is estimated to result in 2.6 million global deaths every year

    - PMLiVE

    Novartis announces positive late-stage results for Leqvio monotherapy in atherosclerotic CVD

    Cardiovascular disease, including heart disease and stroke, is the leading cause of death globally

    - PMLiVE

    J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn

    The company’s medtech division will gain access to a cardiovascular implant device for heart failure

    - PMLiVE

    NewAmsterdam shares positive phase 3 results for CETP inhibitor obicetrapib in HeFH

    Heterozygous familial hypercholesterolaemia affects approximately one in 250 people globally

    - PMLiVE

    Johnson & Johnson to expand cardiovascular capabilities with $13.1bn Shockwave acquisition

    Cardiovascular disease results in an estimated 17.9 million global deaths every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links